The evolution of modern healthcare is increasingly defined by the breaking down of "silos" between medical specialties. Historically, a patient’s heart and lung health were managed separately from their oncology treatments. However, we are now entering an era where the Cardiopulmonary Exercise Testing Market is becoming the backbone of pre-surgical and pre-treatment evaluation. By measuring oxygen uptake ($VO_2$), carbon dioxide production ($VCO_2$), and ventilatory thresholds, clinicians can determine if a patient is physiologically robust enough to undergo the rigors of modern treatment.

This diagnostic precision is particularly vital for those entering the Cancer Biological Therapy Market. Biological therapies, while more targeted than traditional chemotherapy, can place unique stressors on the cardiovascular system. In the US Cancer Biologic Therapy Market, integrated cardio-oncology programs have become the gold standard, ensuring that patients receive life-saving drugs without sustaining permanent heart damage. This trend is mirrored in the US Cardiopulmonary Exercise Testing Market, where high-end metabolic carts are increasingly found in cancer research centers.